Ozelle Introduces the Advanced O-Cyte 1 Hematology Analyzer at ADLM 2026

Ozelle to Launch O-Cyte 1 at ADLM 2026

In a significant advancement for the field of hematology, Ozelle is set to showcase its latest innovation, the O-Cyte 1 automated hematology analyzer, during the ADLM 2026 event in California. This unveiling marks a pivotal moment in the evolution of hematology analysis, integrating cutting-edge AI technology with high-performance capabilities.

The O-Cyte 1 aims to effectively close the longstanding gap in integrating cellular morphology into routine hematological workflows, a challenge that has persistently hindered many laboratories. Traditionally, manual microscopy requires skilled specialists, and while image-based methodologies have broadened visualization capabilities, they often struggle with fitting seamlessly into high-throughput laboratory environments.

Ozelle’s O-Cyte 1 addresses these challenges head-on. By leveraging the AI × CBM (Complete Blood Morphology) framework, this analyzer not only offers succinct morphology intelligence but also streamlines operational efficiency. It processes images of cells and converts them into structured, actionable insights, promoting a transition from mere numerical data to richer, image-based evidence. This feature significantly enhances the consistency of interpretations across various tests.

The compact design of the O-Cyte 1 is complemented by impressive throughput capabilities, handling up to 60 tests per hour independently and potentially scaling up to 360 tests per hour when connected in a cascaded setup. This flexibility is invaluable for clinical settings that demand high efficiency while minimizing operational complexities. Raymond, the head of Ozelle’s North America division, emphasized that this innovation is crafted to enhance practicality and accessibility in daily hematology practices, stating, "O-Cyte 1 reflects our vision for accessible and scalable advanced morphology intelligence."

This year's ADLM presents Ozelle with a platform to showcase not only the O-Cyte 1 but also its expansive clinical hematology portfolio. The global demand for efficient and flexible hematological solutions continues to rise, particularly across diverse markets in North America, Europe, the Middle East, and Asia. Ozelle is committed to supporting these varied clinical scenarios with its robust AI-powered diagnostic systems, tailored for everyday use.

The O-Cyte 1 will be featured at Booth 2517 during the ADLM 2026, taking place from July 28 to July 30 at the Anaheim Convention Center. Attendees are encouraged to visit for an immersive experience with Ozelle's latest innovation. For those unable to attend in person, Ozelle welcomes requests for product briefings and discussions focused on potential regional collaborations.

For more details, visit Ozelle's official site: www.ozellemed.com or contact them directly via email at [email protected]. This launch not only underscores Ozelle's dedication to innovation but also positions the company at the forefront of the next generation of hematology analysis, promising to redefine expectations in laboratory practices.